Indeed, KCTD2 promotes ubiquitination and degradation of the oncogene c-Myc, and reduced KCTD2 mRNA levels are present in glioma cells, promoting tumor growth in vivo [8]. This evidence concerns the gene KCTD2 and central nervous system cancer.